Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

and in the US manufacturers of branded drugs have become adept at constructing patent defences to prevent competition. The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Mr Kim said European payers have waited until both drugs are on the market before launching tenders, in order to drive a hard bargain on the price. Roche has had time to defend Herceptin against ...